[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    Views 561
    Citations 0
    Research Letter
    February 12, 2020

    Gender Identity and Lifetime Prevalence of Skin Cancer in the United States

    Author Affiliations
    • 1Department of Dermatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
    • 2University of Massachusetts Medical School, Worcester
    • 3Department of Dermatology, VA Integrated Service Network (VISN- 1), Jamaica Plain, Massachusetts
    JAMA Dermatol. Published online February 12, 2020. doi:10.1001/jamadermatol.2019.4197

    Gender identity refers to one’s personal sense of gender and includes identifying as cisgender (ie, a gender identity that aligns with the sex assigned at birth), transgender (ie, a gender identity that does not align with the sex assigned at birth), and gender nonconforming (GNC) (ie, a gender identity that does not follow others’ ideas about how a person should look or act based on the sex assigned at birth). There has been increasing national focus on examining cancer risks of transgender and gender-nonconforming (TGNC) patients1 and, although prior research has examined skin cancer prevalence among sexual minority populations,2 this study is the first, to our knowledge, to evaluate skin cancer history by gender identity.